Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 5 de 5
Filter
Add more filters










Database
Language
Publication year range
1.
J Patient Saf ; 17(8): e1697-e1706, 2021 Dec 01.
Article in English | MEDLINE | ID: mdl-34852420

ABSTRACT

OBJECTIVES: The primary objective of this multisite study, High-Alert Medication Stratification Tool-Revised (HAMST-R) phase II, was to assess the content validity of HAMST-R. Secondary outcomes included interrater reliability and ease of use. METHODS: HAMST-R was designed as an objective tool to evaluate high-alert medications (HAMs) at a single site during HAMST-R Phase I. Medication safety experts from 7 health systems across the United States volunteered to participate in this phase II study. Participants completed a demographic survey, oversaw evaluation of 47 HAMs and 35 non-HAMs using HAMST-R, and submitted scores for each medication evaluated. In addition, participants rated each question of HAMST-R on its relevance to assess a medication's safety risk, measured as scale-content validity index. Positive and negative predictive values were evaluated in a post hoc analysis. Interrater reliability was evaluated using the Kendall coefficient of concordance (K), and ease of use was assessed using a mixed-methods approach. RESULTS: Scale-content validity index was 0.80, indicating that the tool was valid. Positive predictive value was 90.5% (95% confidence interval, 87.2%-93.0%), and negative predictive value was 98.2% (95% confidence interval, 95.4%-99.3%). A score of 4 or more differentiated between HAMs and non-HAMs, confirming phase I findings. K was 0.56, indicating moderate agreement. Participants confirmed that the tool was easy to use and plan to incorporate the tool into HAM policies and procedures, formulary review, and safety strategy implementation. CONCLUSIONS: HAMST-R is a valid, objective, and easy to use method that institutions may implement to evaluate a medication's potential safety risk.


Subject(s)
Research Design , Humans , Reproducibility of Results , United States
2.
J Patient Saf ; 17(7): e672-e683, 2021 10 01.
Article in English | MEDLINE | ID: mdl-29232260

ABSTRACT

OBJECTIVE: To develop an objective tool designed to standardize the identification of high-alert medications (HAMs) according to patient safety risk. METHODS: Medications were evaluated using the High-Alert Medication Stratification Tool (HAMST). Tool revision occurred through assessing medications on an organization-approved HAM list and comparing scores with control medications not included on the list. Because of variations in HAMST interpretation by end users in interdisciplinary committees, a revision of the scoring tool was completed to create the High-Alert Medication Stratification Tool-Revised (HAMST-R), and the assessment was repeated. Both tools range from 0 to 10, with 10 describing agents with highest risk. RESULTS: The median (interquartile range [IQR]) initial HAM (n = 44) score using HAMST was 6 (5-7). The median (IQR) control (n = 45) score was 1 (0-2). Using the modified tool, HAMST-R, the median (IQR) HAM score was 4 (4-6) versus 1 (0-1) for controls. Scores for HAMs were significantly higher than controls using both tools (P < 0.001). A HAMST-R score of 4 or higher defines medications as high alert, as this score includes 75% of HAMs and no controls. CONCLUSIONS: Through this exploratory study, clarification of the tool was required to increase its concurrent validity, interrater reliability, and implementation among other health systems. The revised tool, HAMST-R, is a newly developed, objective tool for standardized identification of HAMs. The tool may also be used for prospective identification of medications as high risk to patient safety during formulary review.


Subject(s)
Patient Safety , Humans , Prospective Studies , Reproducibility of Results
3.
Burns ; 46(2): 370-376, 2020 03.
Article in English | MEDLINE | ID: mdl-31420265

ABSTRACT

Burn patients frequently require autograft harvesting to facilitate wound healing, often resulting in significant pain. Liposomal bupivacaine is indicated for administration into a surgical site to produce postsurgical analgesia. The objective of this study was to evaluate efficacy, safety, and duration of postoperative analgesia with liposomal bupivacaine for donor site pain in burn patients. This was an observational, case-control study including adult patients with <20% total body surface area (TBSA) burned who received liposomal bupivacaine for postoperative pain management after autograft harvesting from lower extremity donor site(s). Patients from the case group were matched to historical control patients treated with traditional pain management. The primary outcome was the cumulative pain scores on postoperative day one measured by the area under the curve (AUC0-24). Secondary outcomes included AUC0-72, total milligram morphine equivalents (MME), length of stay, and adverse events. Data were collected in 36 patients who received liposomal bupivacaine, with 21 patients eligible for matching to historical controls. Patients included in the intervention and control groups were well-matched at baseline. Patients in the intervention group had a significantly lower median (IQR) AUC0-24 [578 (408,740) vs. 680 (544,803); p = 0.05] and shorter length of stay [4 days (1,9.5) vs. 6 days (318); p = 0.01]. No differences in adverse events related to the administration of liposomal bupivacaine or opioid-related adverse events were observed. Results indicate liposomal bupivacaine is safe and effective in burn patients. The results of this study add to the limited body of literature examining efficacy in this population.


Subject(s)
Anesthetics, Local/administration & dosage , Bupivacaine/administration & dosage , Burns/surgery , Pain, Postoperative/prevention & control , Tissue and Organ Harvesting/methods , Transplant Donor Site , Adult , Analgesics, Opioid/therapeutic use , Case-Control Studies , Female , Humans , Length of Stay , Liposomes , Male , Middle Aged , Pain Management , Pain, Postoperative/drug therapy , Prospective Studies , Skin Transplantation , Transplantation, Autologous , Treatment Outcome
4.
J Pharm Pract ; 30(2): 223-228, 2017 Apr.
Article in English | MEDLINE | ID: mdl-27000138

ABSTRACT

BACKGROUND: Hospital readmissions have recently gained scrutiny by health systems as a result of their high costs of care and potential for financial penalty in hospital reimbursement. Mobile-integrated health and community paramedicine (MIH-CP) programs have expanded to serve patients at high risk of hospital readmission. Pharmacists have also improved clinical outcomes for patients during in-home visits. However, pharmacists working with a MIH-CP program have not been previously described. This project utilized a novel multidisciplinary Community Paramedicine Team (CPT) consisting of a pharmacist, paramedic, and social worker to target patients with heart failure at high risk of readmission to assist with coordination of care and education. OBJECTIVES: This article describes the development of the CPT, delineation of CPT member responsibilities, and outcomes from pilot visits. METHODS: The CPT visited eligible patients in their homes to provide services. Patients with heart failure who were readmitted within 30 days were eligible for a home visit. RESULTS: A total of 6 patients were seen during the pilot, and 2 additional patients were seen after the pilot. CONCLUSION: Imbedding a pharmacist into a CPT provides a unique expansion of pharmacy services and a novel approach to address hospital readmissions.


Subject(s)
Allied Health Personnel , Community Health Services/methods , Continuity of Patient Care , Patient Care Team , Pharmacists , Professional Role , Aged , Allied Health Personnel/trends , Community Health Services/trends , Continuity of Patient Care/trends , Female , Follow-Up Studies , Humans , Male , Middle Aged , Patient Care Team/trends , Patient Readmission/trends , Pharmacists/trends , Pilot Projects
5.
Am J Health Syst Pharm ; 73(3): 127-32, 2016 Feb 01.
Article in English | MEDLINE | ID: mdl-26796905

ABSTRACT

PURPOSE: The process of developing a workshop to enhance pharmacy residents' precepting skills and confidence in serving as preceptors is described, and survey results indicating the program's effectiveness are presented. SUMMARY: In response to requests from pharmacy residents for structured precepting-specific training to augment their participation in teaching certificate programs, Indianapolis, Indiana-based Eskenazi Health launched a series of annual workshops designed to hone residents' precepting skills. First offered as a half-day program in January 2011, the workshop was expanded in 2014 to a full-day format, with pharmacists from several local residency programs invited to attend. The workshop includes didactic sessions covering a wide range of topics (e.g., the four preceptor roles, techniques for providing effective feedback, strategies for dealing with difficult situations), as well as a panel discussion during which new and experienced preceptors share insights on effective teaching and precepting challenges; continuing-education credit is available. A total of 51 postgraduate year 1 or 2 residents from nine local rotation sites attended the 2014 workshop. The results of surveys administered before and after the workshop indicated that workshop attendance was associated with significant improvement in residents' comfort level in the 24 skill areas covered in the workshop and their ability to serve as copreceptors. CONCLUSION: A workshop was developed to assist pharmacy residents in developing precepting skills. Positive feedback about the program was received from attendees.


Subject(s)
Clinical Competence , Pharmacy Residencies , Preceptorship , Attitude of Health Personnel , Education , Humans , Indiana , Program Development , Surveys and Questionnaires
SELECTION OF CITATIONS
SEARCH DETAIL
...